Benralizumab

What is Benralizumab?

Benralizumab is a targeted biologic medication used in the treatment of specific inflammatory conditions. It is a type of monoclonal antibody, a sophisticated protein designed to bind to a specific target in the body. Marketed under the brand name Fasenra, Benralizumab primarily serves as an add-on maintenance treatment for patients aged 12 years and older with severe eosinophilic asthma. This particular form of asthma is characterized by elevated levels of a type of white blood cell called eosinophils, which play a significant role in airway inflammation and hyperresponsiveness.

Unlike traditional asthma medications that broadly reduce inflammation, Benralizumab offers a more precise approach. It works by specifically targeting the IL-5 receptor alpha subunit, a key component involved in the maturation and survival of eosinophils. By interfering with this pathway, Benralizumab aims to reduce the number of eosinophils in the blood and airways, thereby alleviating symptoms and reducing the frequency of asthma exacerbations in suitable patients.

How Does it Work?

The mechanism of action of Benralizumab is highly specific and central to its effectiveness in treating severe eosinophilic asthma. It functions by directly binding to the IL-5 receptor alpha chain, which is uniquely expressed on the surface of eosinophils and basophils. This binding prevents interleukin-5 (IL-5), a cytokine essential for eosinophil growth and survival, from attaching to its receptor. However, Benralizumab's action goes beyond simply blocking IL-5 signaling.

Once bound to the IL-5 receptor alpha, Benralizumab recruits natural killer (NK) cells to the eosinophil surface. This triggers a process known as Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC). Through ADCC, the NK cells directly induce the programmed death (apoptosis) of the eosinophils. This results in a rapid and profound depletion of eosinophils from the blood, tissues, and airways. By significantly reducing the eosinophil count, Benralizumab helps to lessen the chronic inflammation that underlies severe eosinophilic asthma, leading to improved lung function, reduced asthma attacks, and a decrease in the need for oral corticosteroids.

Medical Uses

The primary medical indication for Benralizumab is as an add-on maintenance treatment for adults and adolescents (12 years and older) with severe eosinophilic asthma. It is specifically intended for patients whose asthma remains poorly controlled despite receiving high-dose inhaled corticosteroids (ICS) in combination with another long-acting asthma control medication, such as a long-acting beta-agonist (LABA).

Patients who benefit most from Benralizumab typically have a history of frequent asthma exacerbations and elevated blood eosinophil counts, indicating an eosinophilic phenotype of asthma. It is crucial to note that Benralizumab is not indicated for the treatment of other eosinophilic conditions or for the relief of acute bronchospasm or status asthmaticus. Its role is strictly for long-term control and prevention of future asthma attacks, complementing existing asthma therapies.

Dosage

Benralizumab is administered as a subcutaneous injection. The typical recommended dose for adults and adolescents (12 years and older) with severe eosinophilic asthma is 30 mg. The dosing schedule involves an initial phase followed by a maintenance phase:

• The first three doses are administered every 4 weeks.
• Subsequent doses are then administered every 8 weeks.

These injections are usually given by a healthcare professional in a clinic or hospital setting. Patients or their caregivers may be trained to administer the injection at home after the initial doses, provided they receive appropriate instruction and supervision. It is critical for patients to adhere strictly to the prescribed dosing schedule and not to discontinue or adjust their other asthma medications without consulting their healthcare provider. Regular follow-up appointments are essential to monitor treatment effectiveness and manage any potential side effects.

Side Effects

Like all medications, Benralizumab can cause side effects, though not everyone experiences them. The most common side effects reported with Benralizumab include:

• Headache: Often mild and transient.
• Pharyngitis: Sore throat or irritation of the throat.
• Injection site reactions: Pain, redness, swelling, or itching at the site of injection.

More serious, though less common, side effects can occur. These may include hypersensitivity reactions, such as rash, urticaria (hives), and in rare cases, anaphylaxis. Patients should be monitored for signs of allergic reactions, particularly after the first few doses. There has also been an increased incidence of herpes zoster (shingles) reported in clinical trials; patients should be advised to seek medical attention if they develop a painful rash.

It is important to remember that Benralizumab does not treat acute asthma attacks. Patients should continue to use their rescue inhalers as needed and seek immediate medical attention for worsening asthma symptoms or severe allergic reactions. Any new or worsening symptoms should be reported to a healthcare professional promptly.

Drug Interactions

Due to its nature as a monoclonal antibody, Benralizumab is not metabolized by cytochrome P450 enzymes or other drug-metabolizing enzymes and transporters. Therefore, it is generally considered to have a low potential for direct pharmacokinetic drug interactions with other commonly used medications. This means that Benralizumab is unlikely to affect how other drugs are processed by the body, and vice versa.

However, it is always important to inform your doctor and pharmacist about all medications you are currently taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements. While no major drug interactions have been identified with conventional asthma treatments (e.g., inhaled corticosteroids, long-acting beta-agonists), caution is advised regarding live attenuated vaccines. It is generally recommended to avoid administering live vaccines during treatment with Benralizumab, as its effect on the immune system could potentially reduce the vaccine's effectiveness or increase the risk of infection. Your healthcare provider will guide you on appropriate vaccination schedules.

FAQ

Q: Is Benralizumab a cure for asthma?

A: No, Benralizumab is not a cure for asthma. It is an add-on maintenance treatment for severe eosinophilic asthma designed to reduce symptoms, improve lung function, and decrease the frequency of asthma attacks. Patients must continue their other prescribed asthma medications as directed by their doctor.

Q: How quickly does Benralizumab start to work?

A: Some patients may experience improvements in asthma symptoms and lung function within a few weeks of starting treatment. However, the full benefits, such as a reduction in asthma exacerbations, often become more apparent over several months of consistent dosing.

Q: Can I stop my other asthma medications once I start Benralizumab?

A: No. It is crucial not to stop or change any of your other asthma medications, including inhaled corticosteroids, without first consulting your healthcare provider. Benralizumab is intended to be used in conjunction with your existing asthma treatment plan.

Q: What should I do if I miss a dose of Benralizumab?

A: If you miss a dose, contact your healthcare provider as soon as possible. They will advise you on when to take your next dose and how to adjust your dosing schedule to ensure optimal treatment effectiveness.

Q: Who is a suitable candidate for Benralizumab?

A: Benralizumab is indicated for adults and adolescents (12 years and older) with severe eosinophilic asthma whose asthma is not adequately controlled with high-dose inhaled corticosteroids plus another asthma control medication.

Products containing Benralizumab are available through trusted online pharmacies. You can browse Benralizumab-based medications at ShipperVIP or Medicenter.

Summary

Benralizumab, known by its brand name Fasenra, represents a significant advancement in the treatment of severe eosinophilic asthma. As a targeted monoclonal antibody, it uniquely binds to the IL-5 receptor alpha on eosinophils, leading to their depletion through Antibody-Dependent Cell-Mediated Cytotoxicity. This precise mechanism helps to reduce airway inflammation, improve lung function, and significantly decrease the frequency of asthma exacerbations in eligible patients.

Administered via subcutaneous injection, Benralizumab offers a convenient dosing schedule after an initial loading phase. While generally well-tolerated, patients should be aware of potential side effects, including headache, pharyngitis, and injection site reactions, and be vigilant for signs of more serious hypersensitivity reactions. It is a critical add-on therapy, not a cure, and should be used in conjunction with existing asthma medications under the guidance of a healthcare professional. Benralizumab provides a valuable option for individuals struggling with severe eosinophilic asthma to achieve better disease control and an improved quality of life.